These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28149757)

  • 21. Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.
    To KKW; Fong W; Cho WCS
    Front Oncol; 2021; 11():635007. PubMed ID: 34113560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
    Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
    Front Immunol; 2021; 12():651086. PubMed ID: 34248939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting.
    Skribek M; Rounis K; Makrakis D; Agelaki S; Mavroudis D; De Petris L; Ekman S; Tsakonas G
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33321730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients.
    Escoin-Perez C; Blasco S; Juan-Vidal O
    Lung Cancer; 2020 Jun; 144():1-9. PubMed ID: 32278215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions.
    Remon J; Vilariño N; Reguart N
    Cancer Treat Rev; 2018 Mar; 64():21-29. PubMed ID: 29454155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review.
    Onoi K; Chihara Y; Uchino J; Shimamoto T; Morimoto Y; Iwasaku M; Kaneko Y; Yamada T; Takayama K
    J Clin Med; 2020 May; 9(5):. PubMed ID: 32384677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress.
    Huang Z; Su W; Lu T; Wang Y; Dong Y; Qin Y; Liu D; Sun L; Jiao W
    Front Pharmacol; 2020; 11():578091. PubMed ID: 33117170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors.
    Nicoś M; Krawczyk P; Crosetto N; Milanowski J
    Front Oncol; 2020; 10():569202. PubMed ID: 33344229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review.
    Naltet C; Besse B
    Transl Lung Cancer Res; 2021 Jun; 10(6):3014-3028. PubMed ID: 34295694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer.
    Fang L; Zhao W; Ye B; Chen D
    Front Oncol; 2021; 11():670313. PubMed ID: 34017689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
    Hendriks LEL; Remon J; Menis J; Besse B
    Transl Lung Cancer Res; 2021 Jun; 10(6):2868-2875. PubMed ID: 34295685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.
    Metro G; Chiari R; Ricciuti B; Rebonato A; Lupattelli M; Gori S; Bennati C; Castrioto C; Floridi P; Minotti V; Chiarini P; Crinò L
    Expert Opin Pharmacother; 2015; 16(17):2601-13. PubMed ID: 26439599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of immunotherapy and radiotherapy in the treatment of brain metastases from non-small cell lung cancer.
    Suwinski R
    J Thorac Dis; 2021 May; 13(5):3315-3322. PubMed ID: 34164224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Ren P; Liu D; Li W
    Cancer Med; 2019 Jul; 8(8):4023-4031. PubMed ID: 31165589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.
    Sun D; Tian L; Zhu Y; Wo Y; Liu Q; Liu S; Li H; Hou H
    Mol Med; 2020 Aug; 26(1):78. PubMed ID: 32791957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.
    Berghoff AS; Venur VA; Preusser M; Ahluwalia MS
    Am Soc Clin Oncol Educ Book; 2016; 35():e116-22. PubMed ID: 27249713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
    Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
    Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.